Drugs /

bay 1905254

Back to Drugs List

Overview

NCI Definition [1]:
A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, BAY 1905254 targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.

Clinical Trials

View Clinical Trials for bay 1905254

Bay 1905254 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bay 1905254, 1 is phase 1 (1 open).

PD-L1 Expression (CPS >= 1) is the most frequent biomarker inclusion criterion for bay 1905254 clinical trials.

Head and neck squamous cell carcinoma and malignant solid tumor are the most common diseases being investigated in bay 1905254 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bay 1905254
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bay 1905254 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bay-1905254, bay1905254, anti-ildr2 monoclonal antibody bay 1905254
Drug Target(s) [2]:
ILDR2
NCIT ID [1]:
C156490

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.